PTX — Prescient Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- AU$56.78m
- AU$47.98m
- AU$0.14m
Annual cashflow statement for Prescient Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 1.46 | 2.04 | 3.13 | 4.05 | 4.46 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.31 | -6.19 | -7.4 | -7.24 | -7.22 |
| Capital Expenditures | -0.004 | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -16 | 12 | 4 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.004 | -16 | 12 | 4 | 0 |
| Financing Cash Flow Items | 0 | -0.698 | 0 | — | -0.413 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.428 | 15.8 | 0.018 | -0.33 | 9.34 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.83 | -6.37 | 4.6 | -3.59 | 2.12 |